Phyllis Dillinger, Women in Bio

Phyllis discusses the importance of making connections in the industry to propel women into leadership roles, and plans for the upcoming BIO International Convention in Boston, Mass. On June 18-21.

Ronald Stotish, President & CEO of AquaBounty, on Animal Biotech and the 2012 BIO International Convention

Hear from Ron Stotish, President & CEO, AquaBounty, as he discusses the challenges facing the animal biotech field and the state of the industry in MA ahead of the 2012 BIO International Convention.

BIO and BVGH on Global Health

BIO's President and CEO Jim Greenwood talks to BIO Ventures for Global Health (BVGH) CEO Don Joseph about global health and BVGH's new report on global health.

Andrew Emmett on PDUFA and the 2012 BIO International Convention

Andrew Emmett, Managing Director, Science & Regulatory Affairs, speaks about the important regulatory issues facing the industry, specifically PDUFA reauthorization, the FDA and regulation. Also, hear his programming highlights from the Achieving Regulatory Approval and Compliance Track at the upcoming 2012 BIO International Convention.

Therapeutic Discovery Project Defending America's Competitiveness in Biotechnology

Capital formation challenges in the industry have forced many biotech companies to halt projects, lay off staff or shutdown all together. Our analysis shows that the industry is approximately one-quarter smaller than it was in 2008.

Therapeutic Discovery Project Helps Scientists Working To Cure Cancer

BIO believes that the level of support provided by the TDP simply cannot meet the needs of the growing biotech field. As evidence of the project's popularity suggests, Congress should consider extending or expanding the project in order to support American innovation and speed the development of life-saving cures.

Therapeutic Discovery Project Is Working to Create & Protect American Jobs

The biotech industry is a thriving sector employing 1.3 million Americans in high quality, high paying jobs.

Laura Shawver, PhD, CEO, Cleave Biosciences

Dr. Shawver discusses why this is an exciting time for the industry, and her experiences as a bench scientist turned CEO and founder of a patient advocacy group.

Bob Coughlin of MassBio Talks Innovation

Bob Coughlin discusses the elements of supportive bioscience industry climates and looks ahead to the 2012 BIO International Convention.

OncoMed Pharmaceuticals SVP/CFO on Emerging Company Capital Formation Testimony

William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals, highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth. Mr. Waddill provided testimony today on behalf of BIO at a Senate Committee on Banking, Housing, and Urban Affairs hearing.